Profarma 2Q26 adjusted EBITDA rises 25.4% to R$ 126.6 million; revenue climbs 31.4% to R$ 4.1 billion
Reuters2026/07/30 02:52- Profarma posted 2Q26 gross revenue of R$ 4.1 billion, up 31.4% year over year; adjusted EBITDA rose 25.4% to R$ 126.6 million.
- Adjusted EBITDA margin narrowed to 3.5% from 3.7%, reflecting the inclusion of newly acquired 4BIO, which ran a 2.2% margin.
- Adjusted net income climbed 23.7% to R$ 31.7 million; operating cash generation over the last 12 months rose 76.5% to R$ 378.3 million.
- Net leverage ended the quarter at 2.9x net debt/EBITDA, including R$ 511 million in acquisition obligations; it would have been 2.2x excluding 4BIO.
- Management highlighted the May 4 acquisition of 4BIO and said logistics synergies should be captured progressively from July, supporting second-half margin gains.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Storage Giant Offers Huge Bonuses Again: Micron Awards Up to 68 Months’ Bonus
Micron Technology has announced record-breaking bonuses for its employees in Taiwan, ranging from 35 to 68 months’ salary, with a minimum cash compensation of 1.7 million New Taiwan dollars. However, the Taoyuan union, representing about two-thirds of Micron’s workers in Taiwan, has refused to accept the offer, insisting that 15% of operating profits be included in the bonus distribution and maintaining the threat of a strike.
Dogecoin ETF Closure Sets October Exit for Bitwise BWOW Holders
Crypto prices
More
